NCT01434602 2022-06-01Phase I-II Everolimus and Sorafenib in Recurrent High-Grade GliomasNational Institutes of Health Clinical Center (CC)Phase 1/2 Completed86 enrolled 24 charts
NCT01204476 2016-07-15Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaNational Cancer Institute (NCI)Phase 1 Completed27 enrolled